Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens
Liesbeth E.M. Oosten(Leiden University Medical Center), Hendrik Veelken(University of Freiburg), Daphne de Jong(Amsterdam UMC Location Vrije Universiteit Amsterdam), Martine E.D. Chamuleau(Dutch Cancer Society), Lizan Hardi(Alrijne Ziekenhuis), Marcel Nijland, Marie José Kersten(Amsterdam University Medical Centers), Carin A. Uyl‐de Groot(Erasmus University Rotterdam), Claire Siemes(Erasmus MC Cancer Institute), A. M. P. Demandt(Maastricht University), Wendy B.C. Stevens(Radboud University Nijmegen), L. C. de Wreede(Leiden University Medical Center), Rolf E. Brouwer(Reinier de Graaf Hospital), Frederick W. Thielen(Erasmus University Rotterdam), P. M. Kluin(University Medical Center Groningen), Gustaaf W. van Imhoff, Oscar S. Smeekes(Amsterdam UMC Location University of Amsterdam), Joke W. Baars(The Netherlands Cancer Institute), Jeanette K. Doorduijn(Université Paris Cité)
Cited by 44
Related Papers
Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs
|Cancer Treatment Reviews|2016|609
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
|The Lancet|2021|337
Essential role of stromally induced hedgehog signaling in B-cell malignancies
|Nature Medicine|2007|321